Neutral
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics has commenced concurrent public offerings of $150.0 million in convertible senior notes due 2032 and $100.0 million in common st...